A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

NCT07652736 · clinicaltrials.gov ↗

RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer
Extensive-Stage Small Cell Lung Cancer

Interventions

DRUG: Tislelizumab

Sponsor

BeOne Medicines